Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast cancers. A recently completed phase 3 clinical trial, conducted by researchers at Mass General Brigham and collaborators, shows that combining inavolisib with palbociclib and fulvestrant improves overall survival for patients with advanced PIK3CA-mutated breast cancer. Results of the study are published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting.
This article was originally published on MedicalXpress.com
